Active Ingredient History
Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. It is particularly important for its activity against Pseudomonas aeruginosa and the Enterococcus species. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase when administered alone, and is always co-administered with cilastatin to prevent this inactivation. The bactericidal activity of imipenem results from the inhibition of cell wall synthesis. Its greatest affinity is for penicillin binding proteins (PBPs) 1A, 1B, 2, 4, 5 and 6 of Escherichia coli, and 1A, 1B, 2, 4 and 5 of Pseudomonas aeruginosa. The lethal effect is related to binding to PBP 2 and PBP 1B. Imipenem is marketed under the brand name Primaxin. PRIMAXIN I.M. (Imipenem and Cilastatin for Injectable Suspension) is a formulation of imipenem (a thienamycin antibiotic) and cilastatin sodium (the inhibitor of the renal dipeptidase, dehydropeptidase I). PRIMAXIN I.M. is a potent broad spectrum antibacterial agent for intramuscular administration. NCATS
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Bacterial Infections (approved 1985)
Endocarditis, Bacterial (approved 1985)
Escherichia coli Infections (approved 1985)
Respiratory Tract Infections (approved 1985)
Staphylococcal Infections (approved 1985)
Abdominal Abscess (Phase 2)
Abdominal Injuries (Phase 2/Phase 3)
Abscess (Phase 3)
Acinetobacter baumannii (Phase 3)
Bacteremia (Phase 3)
Bacterial Infections (Phase 4)
beta-Lactamases (Phase 4)
Biliary Tract (Phase 4)
Carbapenems (Phase 4)
Cellulitis (Phase 3)
Communicable Diseases (Phase 1)
Critical Illness (Phase 4)
Cystic Fibrosis (Phase 4)
Digestive System Diseases (Phase 4)
Drugs, Investigational (Phase 3)
Endocarditis (Phase 4)
Enterobacteriaceae Infections (Phase 3)
Febrile Neutropenia (Phase 4)
Fibrosis (Phase 4)
Gram-Negative Bacterial Infections (Phase 4)
Healthcare-Associated Pneumonia (Phase 3)
Hematologic Neoplasms (Phase 4)
Hematopoietic Stem Cell Transplantation (Phase 2/Phase 3)
Imipenem (Phase 2/Phase 3)
Infections ()
Intraabdominal Infections (Phase 4)
Lung Diseases (Phase 2/Phase 3)
Lymphoma (Phase 2)
Neoplasms (Phase 2)
Neutropenia (Phase 4)
Obesity (Phase 4)
Pancreatitis (Phase 4)
Pneumonia ()
Pneumonia, Bacterial (Phase 4)
Pneumonia, Ventilator-Associated (Phase 4)
Pyelonephritis (Phase 3)
Sepsis (Phase 4)
Urinary Tract Infections (Phase 4)
Urination Disorders (Phase 4)
Ventilators, Mechanical (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue